Tools

LEADER 03412cam 2200673 i 4500

001 on1240365378;

003 OCoLC;

005 20220609074945.0;

006 m o d f ;

007 cr |||||||||||;

008 210303s2021 dcu ob f000 0 eng c;

024 8 a| 43-010q| (GPO jacket number);

042 a| pcc;

043 a| n-us---;

049 a| ERE#;

050 4 a| KF27b| .O96 2020m;

074 a| 1016-C (online);

086 0 a| Y 4.OV 2:116-130;

086 0 a| Y 4.OV 2:116-130/ERRATA;

086 0 a| Y 4.OV 2:116-130/ERRATA-2;

088 a| Serial no. 116-130 (United States. Congress. House. Committee on Oversight and Reform);

245 14 a| The role of Purdue Pharma and the Sackler family in the opioid epidemic :b| hearing before the Committee on Oversight and Reform, House of Representatives, One Hundred Sixteenth Congress, second session, December 17, 2020.;

264 1 a| Washington :b| U.S. Government Publishing Office,c| 2021.;

300 a| 1 online resource (iii, 62 pages) +e| 2 errata (1 page);

336 a| textb| txt2| rdacontent;

337 a| computerb| c2| rdamedia;

338 a| online resourceb| cr2| rdacarrier;

500 a| Access ID (govinfo): CHRG-116hhrg43010.;

500 a| "Serial no. 116-130.";

500 a| Errata corrects transcription errors on pages 14 and 27.;

500 a| Errata II corrects transcription errors on page 27.;

500 a| GPO Cataloging Record Distribution Program (CRDP).;

504 a| Includes bibliographical references.;

511 0 a| Hearing witnesses: David Sackler, Former Member of the Board of Directors, Purdue Pharma L.P.; Dr. Kathe Sackler, Former Vice President and Member of the Board of Directors, Purdue Pharma L.P.; Craig Landau, President and CEO, Purdue Pharma L.P..;

518 a| Date of hearing: 2020-12-17.;

588 a| Description based on online resource; title from PDF title page (govinfo, viewed Mar. 3, 2021).;

650 0 a| Opioid abusez| United States.=| ^A1017318;

650 0 a| Pharmaceutical industryx| Corrupt practicesz| United States.=| ^A1449437;

650 0 a| Drugsz| United Statesx| Marketing.=| ^A1017730;

610 20 a| Purdue Pharma L.P.x| Corrupt practices.=| ^A1417261;

650 0 a| Oxycodone abusez| United States.=| ^A906554;

650 7 a| Corruption.2| fast0| (OCoLC)fst01352550;

650 7 a| Drugsx| Marketing.2| fast0| (OCoLC)fst00898840;

650 7 a| Opioid abuse.2| fast0| (OCoLC)fst01430929;

650 7 a| Oxycodone abuse.2| fast0| (OCoLC)fst01739447;

650 7 a| Pharmaceutical industryx| Corrupt practices.2| fast0| (OCoLC)fst01060133;

651 7 a| United States.2| fast0| (OCoLC)fst01204155?| UNAUTHORIZED;

655 7 a| Legislative hearings.2| fast0| (OCoLC)fst01910825;

655 7 a| Legislative hearings.2| lcgft;

776 08 i| Print version:a| United States. Congress. House. Committee on Oversight and Reform.t| Role of Purdue Pharma and the Sackler family in the opioid epidemicw| (OCoLC)1240365655;

856 40 u| https://purl.fdlp.gov/GPO/gpo1522057| 0;

922 a| GOVINFOHRG;

922 a| BIBCONEWb| 20210303;

949 a| Click on web addressw| asish| joyner94;

596 a| 1;

998 a| 5580948;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 5580948-1001l| JNETm| JOYNERr| Ys| Yt| JNE1DOu| 4/9/2021x| EDOCUMENTz| JERESOURCE;

The role of Purdue Pharma and the Sackler family in the opioid epidemic : hearing before the Committee on Oversight and Reform, House of Representatives, One Hundred Sixteenth Congress, second session, December 17, 2020.

Author/creator	United States
Format	Electronic
Publication	Washington : U.S. Government Publishing Office, 2021.
Description	1 online resource (iii, 62 pages) + 2 errata (1 page)
Supplemental Content	https://purl.fdlp.gov/GPO/gpo152205
Subjects	Purdue Pharma L.P.--Corrupt practices. Opioid abuse--United States. Pharmaceutical industry--Corrupt practices. --United States. Drugs--United States. --Marketing. Oxycodone abuse--United States.

General note	Access ID (govinfo): CHRG-116hhrg43010.
General note	"Serial no. 116-130."
General note	Errata corrects transcription errors on pages 14 and 27.
General note	Errata II corrects transcription errors on page 27.
General note	GPO Cataloging Record Distribution Program (CRDP).
Bibliography note	Includes bibliographical references.
Performer	Hearing witnesses: David Sackler, Former Member of the Board of Directors, Purdue Pharma L.P.; Dr. Kathe Sackler, Former Vice President and Member of the Board of Directors, Purdue Pharma L.P.; Craig Landau, President and CEO, Purdue Pharma L.P..
Date/time/place of a event note	Date of hearing: 2020-12-17.
Source of description	Description based on online resource; title from PDF title page (govinfo, viewed Mar. 3, 2021).
Issued in other form	Print version: United States. Congress. House. Committee on Oversight and Reform. Role of Purdue Pharma and the Sackler family in the opioid epidemic
Genre/form	Legislative hearings.
Genre/form	Legislative hearings.
Standard identifier#	43-010 (GPO jacket number)
Technical rpt number	Serial no. 116-130 (United States. Congress. House. Committee on Oversight and Reform)
GPO item number	1016-C (online)
Govt. docs number	Y 4.OV 2:116-130
Govt. docs number	Y 4.OV 2:116-130/ERRATA
Govt. docs number	Y 4.OV 2:116-130/ERRATA-2

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

The role of Purdue Pharma and the Sackler family in the opioid epidemic : hearing before the Committee on Oversight and Reform, House of Representatives, One Hundred Sixteenth Congress, second session, December 17, 2020.

Click here for more information about this title

Availability